3D Printing Microstructures for New Drug Delivery Systems with SPHRINT

IMTS

Share this Article

In the recently published, ‘SPHRINT – Printing Drug Delivery Microspheres from Polymeric Melts,’ authors Tal Shpigel, Almog Uziel, and Dan Y. Lewitus explore better ways to offer sustained release pharmaceuticals via 3D printed structures.

Currently, numerous materials are used to create microparticles for sustained drug release, with numerous choices in biodegradable materials, such as include poly(lactic acid) (PLA), polyglycolic acid (PGA), their copolymer poly(lactic-co-glycolic) acid (PLGA) and polycaprolactone.

“Numerous microparticle-based depots products are FDA approved, amongst them are: Zmax® (Azithromycin), Decapeptyl®/Trelstar® (Triptorelin), Vivitrol® (Naltrexone), Arestin® (Minocycline), Risperdal® Consta® (Risperidone), Sandostatin® LAR Depot (Octreotide), Nutropin Depot® (Somatropin), Lupron Depot® (Leuprolide), DepoCyt® (Cytarabine), DepoDur® (Morphine), Bydureon® (Exenatide) Somatuline LA (Lanreotide) [1] and recently approved ZILRETTA™ (triamcinolone acetonide),” state the authors.

Frames obtained from high-speed imaging capturing the evolution of the shape of a molten 30% IBU-PCL blend interacting with either a superoleophobic surface (top) and preserving its spherical shape after 1.8 s or an aluminum surface (bottom), in which the droplet gradually flattens (See SI Video 4 and SI Video 5, respectively). Scale bar: 500 µm. These frames emphasis the significance of using non-wetting surfaces responsible for the formation of spherical droplets.

With the advent of 3D printing and inkjet technology, researchers have experimented with numerous techniques. Many have encountered obstacles though, and challenges regarding methods relying on both inkjet printing and those that are solvent based. Because of that, the researchers created an affordable, yet solvent-free technique for fabricating polymer melts in this study—showing the capability of their SPHRINT technique.

(A) Optical images of (i) neat PCL (154 ± 3°), (ii) 30% IBU-PCL (171 ± 4°), (iii) neat PLGA (167 ± 6°), and (iv) 30% IBU-PLGA (169 ± 4°) microspheres, cooled at room temperature (RT). The values in brackets denote the “sphericity,” expressed as the contact angle values (mean ± S.E.M., n = 10). Scale bar: 200 µm. (B) SEM images of (i) 30% IBU-PCL and (ii) 30% IBU-PLGA microspheres, cooled at RT. Scale bars: 100 µm

Producing drug delivery microspheres from a polymer loaded with a sample drug like ibuprofen, the researchers experimented and conducted an analysis regarding the potential for fabrication of amorphous polymeric microspheres. The researchers evaluated microsphere size, morphology, and texture. Ultimately, they were able to produce ‘near-perfect microspheres.’

“We discovered intricate physical phenomena governing the mechanism of sphere-formation; beside process and performance efficiencies, which in turn render microsphere products more accessible,” stated the researchers. “SPHRINT printing eliminates the use of organic solvents and surfactants; it offers microspheres with reproducible size, shape, and morphology within and between the batches; and the produced microspheres can be easily collected owing to their spherical shape.”

Jetting rate and shear rate were calculated, along with an investigation of melt interaction with the superoleophobic substrate and sphere formation.

In terms of drug encapsulation efficiency, they found that values in connection with SPHRINT were on the highest scale. The authors were encouraged to find ‘stable, consistent, reproducible results.’

“… we believe that SPHRINT may turn microsphere production ubiquitous, allowing for desktop manufacturing of microspheres easily scalable to industrial quantities (with a production rate of 25 Hz, in 1 h, 4.7 g of PCL microspheres may be printed from a single printing head). Finally, SPHRINT may provide a new dimension in reservoir-injectable drug delivery technologies, enabling the employment of multifarious polymers for microsphere production and tuned release profiles,” concluded the researchers.

3D printing has been used in connection with a variety of different drug delivery systems, from experimenting with microreservoirs to hydrophilic matrices, and even spermbots. What do you think of this news? Let us know your thoughts; join the discussion of this and other 3D printing topics at 3DPrintBoard.com.

[Source / Images: ‘SPHRINT – Printing Drug Delivery Microspheres from Polymeric Melts’]

Share this Article


Recent News

Will There Be a Desktop Manufacturing Revolution outside of 3D Printing?

Know Your Würth: CEO AJ Strandquist on How Würth Additive Can Change 3D Printing



Categories

3D Design

3D Printed Art

3D Printed Food

3D Printed Guns


You May Also Like

Featured

Pressing Refresh: What CEO Brad Kreger and Velo3D Have Learned About Running a 3D Printing Company

To whatever extent a business is successful thanks to specialization, businesses will nonetheless always be holistic entities. A company isn’t a bunch of compartments that all happen to share the...

Würth Additive Launches Digital Inventory Services Platform Driven by 3D Printing

Last week, at the Additive Manufacturing Users’ Group (AMUG) Conference in Chicago (March 10-14), Würth Additive Group (WAG) launched its new inventory management platform, Digital Inventory Services (DIS). WAG is...

Featured

Hypersonic Heats Up: CEO Joe Laurienti on the Success of Ursa Major’s 3D Printed Engine

“It’s only been about 24 hours now, so I’m still digesting it,” Joe Laurienti said. But even via Zoom, it was easy to notice that the CEO was satisfied. The...

Featured

3D Printing’s Next Generation of Leadership: A Conversation with Additive Minds’ Dr. Gregory Hayes

It’s easy to forget sometimes that social media isn’t reality. So, at the end of 2023, when a burst of doom and gloom started to spread across the Western world’s...